Spine Art

Key Findings

• Economic: Israeli medical-equipment distributor Amos Gazit Ltd. publicly advertised SpineArt products on 28 October 2026. This establishes an advertised distribution channel; actual orders, contractual status, sales values and customer identities remain unconfirmed.^{1, 2}
• Economic: A historical, search-indexed company homepage explicitly included Israel among Spineart’s served markets. Its precise publication and removal dates, and any cessation of Israeli commercial activity, remain unverified.^{3, 4, 5}
• Political: No public evidence identified of company statements supporting Israeli military operations, relevant political lobbying, military-support donations or settlement sponsorship in the supplied audits.^{5, 6, 7}
• Not found: No public evidence identified of Israeli military contracts, weapons supply, surveillance provision or settlement-specific deployment. The documented robotics partnerships concern civilian spinal surgery.^{8, 9, 10}

Target Profile

Executive Summary

Spineart SA is a Swiss medical-technology company founded in Geneva in 2005. Its documented business concerns spinal implants, surgical instruments and enabling technologies for surgeons and hospitals across more than 60 countries. The four audits identify an Israel-related commercial nexus through medical-device marketing, while finding no public evidence of a military, surveillance or settlement-specific relationship.^{5, 8, 9, 10}

The strongest economic evidence is distributor-controlled: Amos Gazit Ltd., an Israeli medical-equipment distributor, lists SpineArt among its represented manufacturers and maintains a dedicated product category. Both were observed during research on 28 October 2026. These records establish an advertised route to the Israeli market, but do not establish the arrangement’s commencement, importer of record, contractual duration, actual orders, deliveries, revenues or customer locations. Continued website visibility after July and November 2024 cannot independently establish uninterrupted shipments during that period.^{1, 2}

A separate historical company-controlled homepage included Israel in a country list under “+60 markets.” The indexed content incorporated news dated 5 June 2025, but no independently accessible, timestamped archive capture of the exact listing was verified. The current homepage examined on 28 October 2026 omitted that country list; the company profile continued to describe operations across more than 60 countries. Neither the historical listing nor its absence from the redesigned homepage establishes a reliable first-publication date, removal date or commercial exit.^{3, 4, 5, 14}

The principal countervailing findings are substantial. No public evidence identified of IDF or Israeli Ministry of Defence contracts, military logistics, weapons components, Israeli surveillance technology provision, settlement facilities or settlement customers. The documented eCential Robotics and SpinEM Robotics relationships concern surgical navigation and robotic assistance, including a named clinical deployment in California. No public evidence identified of Israel-Palestine advocacy, military-support donations or relevant political lobbying by the company in the supplied record.^{5, 6, 8, 9, 15}

The fixed, human-vetted V6.6 result is BRS 131, Tier E (Minimal/No Complicity). Economic activity supplies the only nonzero domain score, Economic 1.57; military, digital and political domain scores are 0.00. This classification preserves the documented commercial connection while retaining the audits’ limits on transaction verification, military attribution, political conduct and territorial specificity.

Timeline of Relevant Events

Corporate Overview

The target is Swiss Spineart SA, registered under CHE-112.355.249. Its official directory identifies headquarters in Plan-les-Ouates, a manufacturing location in Reignier-Esery, France, and international operations in the United States, Germany, Spain, Italy and the United Kingdom. No dedicated Israeli Spineart office appears in that directory. This establishes the disclosed footprint, rather than proving the absence of independent distributors or Israeli end-users.^{4, 10}

Named operating entities include Spineart USA Inc., Spineart Deutschland GmbH, Spineart España SLU, Spineart Italia S.R.L. and SPINEART (UK) LTD. The directory does not establish the exact equity ownership of each entity. The UK company is separately registered under number 08328402; its significant-control filings concern that legal entity and cannot be converted into ownership percentages for the Swiss parent.^{10, 17, 20}

Gimv and EGS Beteiligungen are documented investors. Gimv’s reported 45.4% beneficial interest is dated 30 September 2025; EGS describes its holding as a minority investment. Those disclosures should not be combined into an invented complete ownership allocation. The September 2025 financing identifies both investors but does not resolve all remaining beneficial holdings.^{11, 12, 24}

SpinEM Robotics is a documented investee, with the precise current ownership percentage and control rights unestablished. eCential Robotics is a technology partner, rather than a verified Spineart subsidiary. The Meditech Spine document establishes an acquisition agreement and anticipated closing, not independently verified completion or current ownership.^{8, 19, 21}

Amos Gazit is the identified Israeli commercial intermediary. The evidence establishes distributor advertising, not a verified Israeli subsidiary, franchise agreement or Spineart-controlled local operation. Likewise, Joinsmart Biomedical’s separate listing of Spineart and Israeli manufacturer CarboFix in one distributor portfolio does not establish a direct relationship between those manufacturers.^{1, 2, 26}

Entity separation also matters for similarly named businesses: the political audit identifies SPINE ART LIMITED, UK company number 07556916, as a separate registration whose ownership by Swiss Spineart SA was not established.²⁷

Domain Summaries

Military: Military

Mechanism of Involvement

No public evidence identified of direct Spineart contracts with the IDF, Israeli Ministry of Defence or Israeli state security bodies. The military audit likewise found no public evidence of defence-prime integration, military base services, military medical logistics, weapons production, militarised product variants or military infrastructure activity. The documented portfolio concerns implants, surgical instruments and clinical technologies.^{5, 10}

Spineart’s robotics relationships do not establish a military mechanism. The December 2022 eCential agreement concerns spinal-surgery applications and commercialisation of a surgical platform. The April 2024 SpinEM investment concerns navigation and robotic assistance for spinal surgery. The named July 2024 deployment was at Providence St. Joseph Hospital in California.^{8, 15, 21}

No public evidence identified of Spineart supplying Elbit Systems, Israel Aerospace Industries, Rafael or Israel Military Industries, or of these surgical technologies being developed for weapons targeting, fire control or kinetic military automation. The verified intended purposes remain clinical.^{5, 8, 28}

Counter-Arguments and Evidence Limits

The company’s strongest defence is affirmative evidence of civilian purpose: the products and named deployments concern spinal treatment, surgical planning and hospital workflows. Robotic assistance, tracking and navigation are insufficient grounds for a military classification without an evidenced military customer, deployment or adapted product.^{8, 9, 15, 28}

The advertised Israeli distribution channel does not identify a military recipient. No public evidence identified of a named Israeli government tender, IDF procurement contract, military hospital delivery or military end-user certificate. Undisclosed customers remain an evidence gap; they cannot be treated as identified military customers.^{1, 2}

The zero military score therefore reflects the audited public record. No qualifying military supply relationship was established from which to assess renewal, withdrawal or cessation. Medical-development financing after the audit’s reference dates does not itself establish continued military support.²⁴

Named Entities and Evidence Map

Digital: Digital

Mechanism of Involvement

Spineart has documented digital surgical capabilities: navigation, semi-automated planning, patient-movement compensation and robotic-assisted screw placement. The PERLA TL applications integrate implants and instruments with eCential Robotics’ Op.n platform. Regulatory milestones in March 2025 and August 2026 concern navigation and robotic-assisted medical procedures.^{9, 23, 29}

No public evidence identified of Israeli-origin cybersecurity procurement in the reviewed disclosures, Israeli surveillance or biometric systems, offensive cyber products, Israeli military intelligence contracts, Project Nimbus participation or Israeli data-centre operations. These are negative findings within the reviewed record, rather than a complete inventory of all undisclosed enterprise technology.^{5, 10, 29}

The privacy statement permits third-party hosting, maintenance, analytics and communications services without naming the processors. It also describes international processing, including in the United States. Consequently, the record does not establish the nationality of every vendor, exact hosting regions or the complete architecture for surgical data.³⁰

Counter-Arguments and Evidence Limits

The strongest defence is the documented medical function of the systems and absence of an evidenced Israeli security deployment. Automated registration, anatomical navigation and robotic placement should not be recast as military AI, population surveillance or autonomous targeting. The public documentation does not establish a particular machine-learning model or training dataset.^{9, 29}

No public evidence identified that Spineart’s website information, customer records or surgical application data are hosted in Israel. Nevertheless, unnamed processors and incomplete infrastructure disclosures prevent a categorical statement that every relevant service provider has been identified. The privacy statement was last updated on 12 January 2021 and is historical policy evidence, not a verified October 2026 infrastructure inventory.³⁰

The historical Israel market listing establishes a commercial geographical association, not an Israeli software contract or security customer. No public evidence identified of PERLA or eCential systems supplied by Spineart for Israeli military surveillance, operational intelligence or settlement deployment.^{3, 9, 29}

Named Entities and Evidence Map

Economic: Economic

Mechanism of Involvement

The economic mechanism is an advertised Israeli distribution channel for Spineart medical devices. Amos Gazit’s medical-partner listing and dedicated SpineArt category provide identifiable evidence of products marketed through an Israeli intermediary. The category remained publicly accessible on 28 October 2026.^{1, 2}

The historical company-controlled market list provides separate support for Spineart’s presentation of Israel as a served market. Legal notices identify Spineart SA and its Digital Communication Department as publisher. However, the historical listing lacks a verified timestamped capture, and its exact publication history remains unresolved.^{3, 4, 14}

The verified mechanism is neither an identified Israeli subsidiary nor a documented investment in Israeli industry. No public evidence identified of Spineart acquiring an Israeli operating company, establishing an Israeli facility, holding Israeli tax residency or financing Israeli sovereign debt, defence contractors or settlement enterprises.^{4, 10, 24, 25}

The confirmed €10 million SpinEM investment must remain separate from the Israeli distribution evidence. The supplied disclosures concern surgical technology, identify French organisational context and establish no Israeli operating location. Similarly, Spineart’s September 2025 capital increase and September 2026 refinancing identify Spineart as recipient or borrower, without establishing Israeli state or settlement beneficiaries.^{21, 24, 25, 28}

Counter-Arguments and Evidence Limits

The company’s strongest defence is that the evidenced connection concerns civilian medical products and distributor advertising. A product category does not disclose shipment volumes, customer identities, payments, distributor profits, tax contributions or market share. No public evidence identified quantifying Spineart’s Israel-related revenue or economic significance.^{1, 2, 5}

The listing remained visible after 19 July 2024 and November 2024, but this observation does not establish deliveries throughout the intervening period. Actual order activity and contractual status on the research date remain unconfirmed. Conversely, removal of the historical country list from the current homepage is insufficient evidence of commercial withdrawal.^{1, 3, 14}

Settlement attribution is unsupported. No public evidence identified of a settlement-based distributor, named settlement hospital, settlement-origin product or delivery to a customer in the occupied West Bank, East Jerusalem or occupied Golan Heights. The Israeli market channel cannot be expanded into a settlement mechanism without customer-specific evidence.^{1, 2, 10}

Investor relationships and shared distributor portfolios also require restraint. Gimv and EGS financing does not establish Israeli state financing by Spineart; Joinsmart’s representation of both Spineart and CarboFix does not establish direct procurement between them.^{24, 26}

Named Entities and Evidence Map

Political: Political

Mechanism of Involvement

No public evidence identified of an official Spineart statement endorsing Israeli military operations, settlement expansion or a specific Israel-Palestine position. No public evidence identified of relevant lobbying, anti-BDS activity, military-support donations, settlement sponsorship or political resource mobilisation. Reviewed corporate communications concern medical products, clinical development, investment and international expansion.^{5, 6, 24}

No public evidence identified of Israel-Palestine-related employee discipline, suppression of political expression or platform censorship. The documented PERLA technology serves surgical workflows; the audit did not establish a political-content platform or moderation function.^{5, 9}

No public evidence identified of an Israeli government controlling stake, state-appointed director, golden share or constitutional obligation to advance Israeli geopolitical objectives. The documented founding purpose is clinical and engineering development in Geneva.^{4, 5, 16}

Counter-Arguments and Evidence Limits

The strongest defence is the absence of evidenced political acts and the civilian subject matter of the company’s communications. Medical-market participation alone does not establish endorsement of government policy. Neither capital raising nor US medical-device clearance establishes political support for Israel.^{9, 24}

The political audit did not identify a specific Israeli distributor in the corporate disclosures it reviewed; the economic audit separately identified Amos Gazit through distributor-controlled pages. These findings are compatible: the commercial channel is documented, while its contractual terms remain unresolved. That evidence does not supply a political statement or donation.^{1, 2, 10}

No public evidence identified of a specifically documented BDS campaign, settlement-related enforcement proceeding or relevant executive philanthropy. This records the searches’ limits, rather than proving that every private activity or historical communication is known.^{5, 6}

The fixed political inputs are I=2.00, M=0.00, P=0.00, yielding Political 0.00. The nonzero Impact input is not evidence of an additional political act; none should be invented to explain it.

Named Entities and Evidence Map

Complicity Index Score

Method: V6.6. The following values are the final, human-vetted scores supplied for this dossier.

• V_MAX: 1.57 Avg_OTHERS: 0.00
• BRS Score: 131 Tier: E (Minimal/No Complicity)

The advertised Israeli medical-device channel supplies the documented economic nexus underlying V_MAX 1.57; the historical company market listing corroborates market association while retaining its dating limitations.^{1, 2, 3} The three other domain scores remain zero, producing the supplied BRS 131 / Tier E result; no separate reviewed rationale was supplied explaining each numerical input, and the economic magnitude input must not be represented as verified sales volume. This is a scale-free, evidence-only, human-vetted assessment: the fixed values are preserved without converting undisclosed transactions or unresolved relationships into additional findings.

Methodology Note

• Evidence boundary: This dossier compiles only the four supplied domain audits, researched on 28 October 2026. Citations reproduce their source references; unresolved findings retain their qualifications.
• Scoring dimensions: Impact describes the activity type on a scale-free basis; Magnitude describes scale; Proximity describes directness. The supplied final V6.6 values are fixed and are not recalculated.
• Temporal treatment: Verified divestment or exit mitigates historical exposure. Here, neither disappearance of a country list nor continued distributor advertising establishes a commercial cessation date or uninterrupted deliveries.^{1, 3, 14}
• Entity attribution: No transitive guilt is applied. Shared distributors, investor affiliations, partnership status, announced acquisitions and UK control filings are not converted into unsupported supply relationships or parent-company ownership claims.^{19, 20, 26}
• Territorial treatment: A verified settlement operation would count in both Economic and Political. No public evidence identified of such an operation in this record; Israeli distribution alone does not establish settlement activity.^{1, 2, 10}
• Negative findings: “No public evidence identified” records where audit checks found nothing. It does not assert exhaustive access to private contracts, undisclosed customers, internal systems or personal conduct.